RXRX Stock Climbs As Earnings Beat Highlights AI Drug Progress

Recursion Pharmaceuticals Inc. stocks have been trading up by 11.3 percent after upbeat AI drug-discovery partnership developments boosted optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading RXRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Q1 loss came in lighter than expected, with EPS at -$0.22 versus -$0.26, while management reaffirmed RXRX has cash runway into early 2028.
Positive early oncology data and strong Phase 2 signals in familial adenomatous polyposis backed RXRX’s AI-driven discovery story, even as collaboration revenue dipped.
Morgan Stanley nudged its RXRX price target to $5.50 from $5.00, keeping an Equal Weight rating and signaling cautious optimism.
Altitude Lab, Recursion’s accelerator, has helped portfolio companies raise more than $205M since 2020, reinforcing RXRX’s anchor role in Salt Lake City biotech.
New RSU grants for about 3.0M Class A shares show RXRX is still hiring aggressively to build out its AI and clinical teams.

Live Update At 12:32:53 EDT: On Thursday, June 04, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 11.3%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been grinding higher on the chart. Over the past few weeks, Recursion Pharmaceuticals stock has climbed from the $2.80s to close near $3.86 on 2026/06/04. That is a steady uptrend, not a one-day wonder. For short-term traders, this staircase pattern often signals controlled accumulation rather than random noise.

Intraday, RXRX traded a tight but rising range, moving from the low $3.30s in the premarket to near $4.04 before settling just under $3.87. That tells you dip-buyers were active on every small pullback. The 5‑minute candles show VWAP-style support building around the mid-$3.80s.

More Breaking News

Fundamentally, RXRX is still a high-burn biotech. Q1 2026 revenue was about $64.7M, but margins are sharply negative, with heavy research and development spend and EBITDA around -$102M. The key for traders is the balance sheet: roughly $654M in cash and short-term investments, a current ratio near 5.5, and very low debt. That supports management’s guidance that RXRX has runway into early 2028, which reduces near-term dilution risk and gives the AI drug-discovery story time to play out.

Why Traders Are Watching RXRX Momentum

RXRX caught traders’ attention when Q1 numbers dropped. The company posted EPS of -$0.22 versus Wall Street’s -$0.26 expectation. Still a loss, but less red than feared. In this type of early-stage biotech, smaller losses plus strong cash visibility often matter more than current profitability. RXRX also talked up “extremely strong” top-line results relative to consensus, giving bulls another data point to lean on.

The real hook, though, was progress in the AI-enabled pipeline. RXRX highlighted encouraging early clinical data across multiple oncology programs and strong Phase 2 signals in familial adenomatous polyposis. For traders, that means the AI discovery pitch is starting to produce real human data, not just slide-deck claims. When story stocks move from concept to clinical evidence, you frequently see fresh momentum waves as new players pile in.

At the same time, RXRX tightened its cash burn. Free cash flow in Q1 was about -$81M, still heavy but “significantly reduced” versus prior periods, and the company stuck to its guidance that cash should last into early 2028. Lower burn plus long runway is a rare combo in small-cap biotech and helps cap downside when sentiment cools.

Morgan Stanley’s move to raise its RXRX price target to $5.50, while keeping an Equal Weight rating, fits that theme. The bank is acknowledging improving fundamentals without calling for a moonshot. For day traders and swing traders, that kind of cautious upgrade often sets up tradable ranges rather than blow-off tops.

Beyond the numbers, RXRX is building an ecosystem. Its Altitude Lab accelerator has already seen portfolio companies raise more than $205M, land pharma deals, and push programs into the clinic. That positions Recursion Pharmaceuticals as a hub in Salt Lake City biotech. Add in RSU inducement grants for 33 new hires, and you see a company still in expansion mode, using equity to pull in AI and biology talent. There is dilution, but it comes with a clear growth plan.

Conclusion

RXRX sits at an interesting crossroads for active traders. The chart shows a controlled uptrend from the high $2s into the high $3s, with intraday action confirming buyers are willing to support pullbacks. The fundamentals show classic high-risk biotech math — big losses, negative margins — but also sizable cash, minimal leverage, and management promising runway into early 2028. In other words, the clock is ticking, but not fast.

On the story side, RXRX is pushing hard on AI-driven drug discovery and now has early human data to talk about in oncology and familial adenomatous polyposis. Reduced cash burn and continued platform progress help offset softer collaboration revenue, while the Morgan Stanley target bump to $5.50 hints that the Street is slowly warming up. Altitude Lab and ongoing hiring suggest Recursion Pharmaceuticals is not just a single ticker, but a growing regional platform for biotech innovation.

For traders who like momentum mixed with catalysts, RXRX offers both: clinical updates, AI partnership headlines, and ample liquidity on the tape. But it is still a speculative biotech, and that means volatility and risk never go away. As Tim Sykes loves to say, “Patterns repeat because human nature doesn’t change — study the past charts, respect the risk, and always, always cut losses quickly.” That mindset lines up well with a more modern risk-focused approach to trading; as Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” RXRX will reward disciplined chart-readers far more than gamblers chasing hype.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!